MK-3795 / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 0 Diseases   3 Trials   3 Trials   83 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MK-3795 / Merck (MSD)
NCT03108066: MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)

Completed
2
4
US
MK-3795, PT2385, PT-2385
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), National Institutes of Health (NIH)
VHL Gene Mutation, VHL, VHL Syndrome, VHL Gene Inactivation, Von Hippel, Von Hippel-Lindau Disease, Von Hippel's Disease, Von Hippel-Lindau Syndrome, Modifiers of, Clear Cell Renal Cell Carcinoma, Clear Cell RCC, ccRCC
08/23
09/23
NCT02293980: A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

Active, not recruiting
1
110
US
MK-3795, PT2385, PT-2385, HIF-2a, MK-3795, Nivolumab, Opdivo, Cabozantinib, Cabometyx, Bezlutifan, MK-6482
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
ccRCC, RCC, Kidney Cancer, Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
01/17
11/26
NCT04989959: [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma

Recruiting
1
80
US
[18F]PT2385, Positron Emission Tomography/Computed Tomography, PET/CT, Biopsy
Orhan Kemal Oz
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
08/25
08/26

Download Options